Meta-analysis of the curative effect of panax notoginseng saponins in the treatment of diabetic peripheral neuropathy

Abstract

Objective: To study the safety and effectiveness of panax notoginseng saponins (trade name: Xuesaitong) for patients with diabetic peripheral neuropathy. Methods: first, search the literature of randomized controlled trials clinical studies of all patients with diabetic peripheral neuropathy using panax notoginseng saponins or Xuesaitong through CNKI and Wanfang, and set the search time in order to establish the database until January 16, 2021, the documents include English and Chinese documents, and further screening will be carried out according to the inclusion criteria of the documents and the exclusion criteria of the documents, and then the basic information in the included documents and the total effective rate, obvious efficiency and the data on the incidence of adverse reactions was extracted into an Excel table. Finally, RevMan 5.3 software was used to meta-analyze the data to study the safety and effectiveness of panax notoginseng saponins in patients with diabetic peripheral neuropathy. Results: a total of 26 Chinese literatures of randomized controlled trials were included, but there were no English literatures. A total of 1804 patients with diabetic peripheral neuropathy were included. The results of meta-analysis showed that patients with diabetic peripheral neuropathy treated with Panax notoginseng saponins had a significant rate [OR=3.27, 95%CI (2.64, 4.05), Z=10.89, P<0.00001] and a total effective rate [OR=4.60, 95%] CI (3.63, 5.82), P<0.00001] was significantly higher than the control group. Conclusion: patients with diabetic peripheral neuropathy have a better therapeutic effect with total saponins of notoginseng.